表紙
市場調査レポート

D型肝炎:パイプライン製品の分析

Hepatitis D - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245993
出版日 ページ情報 英文 61 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
D型肝炎:パイプライン製品の分析 Hepatitis D - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 61 Pages
概要

D型肝炎とは、D型肝炎ウイルス(HDV、デルタウイルス)が感染し、肝臓を腫れ上がらせるという感染症です。主な症状として、皮膚・眼球の黄疸や関節痛・腹痛、吐き気、食欲不振、倦怠感などがあります。主なリスク要因には、多量の輸血や、静注(IV)薬物・注射薬の乱用、妊娠中の感染などが含まれています。

当レポートでは、世界各国でのD型肝炎治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

D型肝炎の概要

治療薬の開発

  • D型肝炎向けパイプライン製品:概要
  • D型肝炎向けパイプライン製品:比較分析

各企業で開発中のD型肝炎治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

D型肝炎治療薬:開発中の製品の一覧(企業別)

D型肝炎治療薬の開発に従事している企業

  • Alnylam Pharmaceuticals, Inc.
  • BioDiem Ltd
  • Biogenomics Limited
  • Eiger BioPharmaceuticals, Inc.
  • Globeimmune, Inc.
  • Johnson & Johnson
  • REPLICor Inc.
  • SomaGenics Inc.

D型肝炎:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 分子の種類別

薬剤のプロファイル

  • ALN-HDV
  • EBP-921
  • GI-18000
  • hepatitis D vaccine
  • interferon alfa-2b (recombinant)
  • lonafarnib
  • Myrcludex-B
  • REP-9-AC'
  • RNAi Oligonucleotide for Hepatitis D
  • tipifarnib

D型肝炎治療薬:パイプライン製品の最新動向

D型肝炎治療薬開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7896IDB

Summary

Global Markets Direct's, 'Hepatitis D - Pipeline Review, H1 2016', provides an overview of the Hepatitis D pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatitis D
  • The report reviews pipeline therapeutics for Hepatitis D by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatitis D therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis D therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatitis D

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis D
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis D Overview
  • Therapeutics Development
    • Pipeline Products for Hepatitis D - Overview
    • Pipeline Products for Hepatitis D - Comparative Analysis
  • Hepatitis D - Therapeutics under Development by Companies
  • Hepatitis D - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis D - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hepatitis D - Products under Development by Companies
  • Hepatitis D - Products under Investigation by Universities/Institutes
  • Hepatitis D - Companies Involved in Therapeutics Development
    • Alnylam Pharmaceuticals, Inc.
    • BioDiem Ltd
    • Eiger BioPharmaceuticals, Inc.
    • Globeimmune, Inc.
    • REPLICor Inc.
    • SomaGenics, Inc.
    • Spring Bank Pharmaceuticals, Inc.
  • Hepatitis D - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ALN-HDV - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GI-18000 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis D vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lonafarnib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Myrcludex-B - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REP-2139 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • REP-2165 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RNAi Oligonucleotide for Hepatitis D - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SB-9200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vanitaracin A - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hepatitis D - Recent Pipeline Updates
  • Hepatitis D - Dormant Projects
  • Hepatitis D - Product Development Milestones
    • Featured News & Press Releases
      • Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016
      • Mar 30, 2016: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Meeting
      • Mar 23, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection
      • Mar 14, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School
      • Jan 19, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 3) Study at National Institutes of Health
      • Jan 06, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School in Hannover, Germany
      • Jul 20, 2015: The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus Infected Patients
      • Jun 30, 2015: Replicor Discloses Updated Clinical Trial Data to the Global Virus Hepatitis Summit in Berlin
      • Jun 10, 2015: Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June
      • Apr 29, 2015: Significant Reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian Patients with HBV / HDV Co-Infection
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis D, H1 2016
  • Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Hepatitis D - Pipeline by BioDiem Ltd, H1 2016
  • Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2016
  • Hepatitis D - Pipeline by Globeimmune, Inc., H1 2016
  • Hepatitis D - Pipeline by REPLICor Inc., H1 2016
  • Hepatitis D - Pipeline by SomaGenics, Inc., H1 2016
  • Hepatitis D - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hepatitis D Therapeutics - Recent Pipeline Updates, H1 2016
  • Hepatitis D - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Hepatitis D, H1 2016
  • Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top